Advice
following an abbreviated submission:
trifarotene (Aklief®) is accepted for use within NHSScotland.
Indication under review: for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.
Trifarotene provides an additional treatment choice in the therapeutic class of topical retinoids.
Download detailed advice727KB (PDF)
Medicine details
- Medicine name:
- trifarotene (Aklief)
- SMC ID:
- SMC2441
- Indication:
Cutaneous treatment of Acne Vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 September 2022